Macular Degeneration clinical trials at UCLA
11 in progress, 4 open to eligible people
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
open to eligible people ages 50-89
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood…
Pasadena, California and other locations
ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
open to eligible people ages 50 years and up
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2…
Los Angeles, California and other locations
ALK-001 on Stargardt Disease
open to eligible people ages 8-70
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.…
Los Angeles, California and other locations
Non Exudative AMD Imaged With SS-OCT- Extension
open to all eligible people
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal…
Los Angeles, California and other locations
Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Los Angeles, California and other locations
Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Sorry, in progress, not accepting new patients
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Encino, California and other locations
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Sorry, not currently recruiting here
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Los Angeles, California and other locations
Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Sorry, in progress, not accepting new patients
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study …
Los Angeles, California and other locations
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Sorry, in progress, not accepting new patients
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either…
Los Angeles, California and other locations
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Los Angeles, California and other locations
GARM II: A Study on the Genetics of Age-related Maculopathy
Sorry, in progress, not accepting new patients
The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65…
Los Angeles, California and other locations
Our lead scientists for Macular Degeneration research studies include Pradeep S. Prasad, MD, MBA Michael S. Ip, MD SriniVas Sadda, MD Michael Gorin, MD, PhD.
Last updated: